These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 28095731)

  • 1. N-Palmitoylethanolamine-Oxazoline as a New Therapeutic Strategy to Control Neuroinflammation: Neuroprotective Effects in Experimental Models of Spinal Cord and Brain Injury.
    Impellizzeri D; Cordaro M; Bruschetta G; Siracusa R; Crupi R; Esposito E; Cuzzocrea S
    J Neurotrauma; 2017 Sep; 34(18):2609-2623. PubMed ID: 28095731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Palmitoylethanolamine-oxazoline (PEA-OXA): A new therapeutic strategy to reduce neuroinflammation, oxidative stress associated to vascular dementia in an experimental model of repeated bilateral common carotid arteries occlusion.
    Impellizzeri D; Siracusa R; Cordaro M; Crupi R; Peritore AF; Gugliandolo E; D'Amico R; Petrosino S; Evangelista M; Di Paola R; Cuzzocrea S
    Neurobiol Dis; 2019 May; 125():77-91. PubMed ID: 30660740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury.
    Esposito E; Paterniti I; Mazzon E; Genovese T; Di Paola R; Galuppo M; Cuzzocrea S
    Brain Behav Immun; 2011 Aug; 25(6):1099-112. PubMed ID: 21354467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of N-palmitoylethanolamine-oxazoline on comorbid neuropsychiatric disturbance associated with inflammatory bowel disease.
    Cordaro M; Scuto M; Siracusa R; D'amico R; Filippo Peritore A; Gugliandolo E; Fusco R; Crupi R; Impellizzeri D; Pozzebon M; Alfonsi D; Mattei N; Marcolongo G; Evangelista M; Cuzzocrea S; Di Paola R
    FASEB J; 2020 Mar; 34(3):4085-4106. PubMed ID: 31950563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution.
    Skaper SD; Facci L; Barbierato M; Zusso M; Bruschetta G; Impellizzeri D; Cuzzocrea S; Giusti P
    Mol Neurobiol; 2015 Oct; 52(2):1034-42. PubMed ID: 26055231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma.
    Paterniti I; Impellizzeri D; Crupi R; Morabito R; Campolo M; Esposito E; Cuzzocrea S
    J Neuroinflammation; 2013 Feb; 10():20. PubMed ID: 23374874
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Fusco R; Scuto M; Cordaro M; D'Amico R; Gugliandolo E; Siracusa R; Peritore AF; Crupi R; Impellizzeri D; Cuzzocrea S; Di Paola R
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Protective Effects of Pre- and Post-Administration of Micronized Palmitoylethanolamide Formulation on Postoperative Pain in Rats.
    Siracusa R; Fusco R; Cordaro M; Peritore AF; D'Amico R; Gugliandolo E; Crupi R; Genovese T; Evangelista M; Di Paola R; Cuzzocrea S; Impellizzeri D
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33080989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer's disease models: the control of neuroinflammation.
    Paterniti I; Cordaro M; Campolo M; Siracusa R; Cornelius C; Navarra M; Cuzzocrea S; Esposito E
    CNS Neurol Disord Drug Targets; 2014; 13(9):1530-41. PubMed ID: 25106636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury.
    Paterniti I; Impellizzeri D; Di Paola R; Navarra M; Cuzzocrea S; Esposito E
    J Neuroinflammation; 2013 Jul; 10():91. PubMed ID: 23880066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury.
    Genovese T; Esposito E; Mazzon E; Di Paola R; Meli R; Bramanti P; Piomelli D; Calignano A; Cuzzocrea S
    J Pharmacol Exp Ther; 2008 Jul; 326(1):12-23. PubMed ID: 18367664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice.
    Impellizzeri D; Peritore AF; Cordaro M; Gugliandolo E; Siracusa R; Crupi R; D'Amico R; Fusco R; Evangelista M; Cuzzocrea S; Di Paola R
    FASEB J; 2019 Oct; 33(10):11364-11380. PubMed ID: 31344333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Pentadecyl-2-Oxazoline, the Oxazoline of Pea, Modulates Carrageenan-Induced Acute Inflammation.
    Petrosino S; Campolo M; Impellizzeri D; Paterniti I; Allarà M; Gugliandolo E; D'Amico R; Siracusa R; Cordaro M; Esposito E; Di Marzo V; Cuzzocrea S
    Front Pharmacol; 2017; 8():308. PubMed ID: 28611664
    [No Abstract]   [Full Text] [Related]  

  • 14. A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation.
    Esposito E; Impellizzeri D; Bruschetta G; Cordaro M; Siracusa R; Gugliandolo E; Crupi R; Cuzzocrea S
    Eur J Pharmacol; 2016 Jul; 782():107-18. PubMed ID: 27095683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats.
    Ahmad A; Genovese T; Impellizzeri D; Crupi R; Velardi E; Marino A; Esposito E; Cuzzocrea S
    Brain Res; 2012 Oct; 1477():45-58. PubMed ID: 23046519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergic Therapeutic Potential of PEA-Um Treatment and NAAA Enzyme Silencing In the Management of Neuroinflammation.
    Casili G; Lanza M; Campolo M; Siracusa R; Paterniti I; Ardizzone A; Scuderi SA; Cuzzocrea S; Esposito E
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NAAA inhibitor F96 attenuates BBB disruption and secondary injury after traumatic brain injury (TBI).
    Li Y; Zhou P; Hu T; Ren J; Xu Y; Qiu Y; Lu C; Li Y
    Eur J Pharmacol; 2021 Dec; 912():174561. PubMed ID: 34655598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation.
    Esposito G; Capoccia E; Turco F; Palumbo I; Lu J; Steardo A; Cuomo R; Sarnelli G; Steardo L
    Gut; 2014 Aug; 63(8):1300-12. PubMed ID: 24082036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective Effects of Co-UltraPEALut on Secondary Inflammatory Process and Autophagy Involved in Traumatic Brain Injury.
    Cordaro M; Impellizzeri D; Paterniti I; Bruschetta G; Siracusa R; De Stefano D; Cuzzocrea S; Esposito E
    J Neurotrauma; 2016 Jan; 33(1):132-46. PubMed ID: 25046306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice.
    Ahmad A; Crupi R; Impellizzeri D; Campolo M; Marino A; Esposito E; Cuzzocrea S
    Brain Behav Immun; 2012 Nov; 26(8):1310-21. PubMed ID: 22884901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.